US20110142963A1 - Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells - Google Patents

Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells Download PDF

Info

Publication number
US20110142963A1
US20110142963A1 US12/923,846 US92384610A US2011142963A1 US 20110142963 A1 US20110142963 A1 US 20110142963A1 US 92384610 A US92384610 A US 92384610A US 2011142963 A1 US2011142963 A1 US 2011142963A1
Authority
US
United States
Prior art keywords
weight
comprised
amount
parts
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/923,846
Other languages
English (en)
Inventor
Chen-Yu Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20110142963A1 publication Critical patent/US20110142963A1/en
Priority to US13/613,654 priority Critical patent/US8449929B2/en
Priority to US13/613,793 priority patent/US20130011499A1/en
Priority to US13/613,774 priority patent/US20130011503A1/en
Priority to US13/613,691 priority patent/US8394430B2/en
Priority to US13/613,714 priority patent/US8420134B2/en
Priority to US13/868,253 priority patent/US8551539B1/en
Priority to US13/873,828 priority patent/US8668940B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells and, more particularly, to herbal medicinal compositions and extracts thereof for inhibiting growth of lung cancer cells.
  • Cancers have been one of ten leading causes of death in the last continuous 27 years.
  • the main cause of cancer is abnormality of cells which undergo self-division continuously to form more and more abnormal cells, i.e., cancers.
  • cancer stem cells In common tumor cells, some cancer cells have characteristics of stem cells. Although such cancer cells are in a small number, they can undergo cell division and differentiation continuously, similar to stem cells, and thus are so called “cancer stem cells”. Since cancer stem cells have extremely high drug resistance, it is difficult for chemotherapeutic agents of modern (Western) medicine to exterminate them. Accordingly, it is often heard that cancer recurrence happens in many patients post-chemotherapy. In addition, standard therapies currently known in biomedical science are still unable to kill such cancer stem cells.
  • the object of the present invention is to provide a herbal medicinal composition and an extract thereof for inhibiting growth of cancer cells such as lung cancer cells.
  • one aspect of the present invention provides a herbal medicinal composition for inhibiting cancer cells including: Gentianae Scabrae Radix ( Gentiana scabra Bunge), Scutellariae Radix ( Scutellaria baicalensis Georgi), Gardeniae Fructus ( Gardenia jasminoides Ellis), Anelicae Sinensis Radix ( Angelica sinensis Diels), Rehmanniae Radix ( Rehmannia glutinosa Libosch. f.
  • Gentianae Scabrae Radix Gentiana scabra Bunge
  • Scutellariae Radix Scutellaria baicalensis Georgi
  • Gardeniae Fructus Gardenia jasminoides Ellis
  • Anelicae Sinensis Radix Angelica sinensis Diels
  • Rehmanniae Radix Rehmannia glutinosa Libosch. f.
  • hueichingensis Chao et Schih Hsiao
  • Hocquartiae Caulis Hocquartia manshuriensis ( Kom.) Nakai)
  • Bupleuri Radix Bupleurum falcatum Linne
  • Plantaginis Semen Plantago asiatica Linne
  • Atractylodis Rhizoma Atractylodes lancea De Candolle
  • Alismatis Rhizoma Alisma plantago—aquatica L. var. orientate SAM.
  • Glycyrrhizae Radix Glycyrrhiza uralensis Fischer et DC).
  • This herbal medicinal composition is extracted, i.e., Gentianae Scabrae Radix, Scutellariae Radix, Gardeniae Fructus, Anelicae Sinensis Radix, Rehmanniae Radix, Hocquartiae Caulis, Bupleuri Radix, Plantaginis Semen, Atractylodis Rhizoma, Alismatis Rhizoma, and Glycyrrhizae Radix are mixed, extracted with water under heating, and then filtrated to remove the dreg thereof.
  • a herbal medicinal extract can be obtained and it also can inhibit growth of cancer cells.
  • the Gentianae Scabrae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Scutellariae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Gardeniae Fructus is comprised in an amount of 1.5-6 parts by weight
  • the Anelicae Sinensis Radix is comprised in an amount of 1.5-6 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Hocquartiae Caulis is comprised in an amount of 1.5-6 parts by weight
  • the Bupleuri Radix is comprised in an amount of 1.5-6 parts by weight
  • the Plantaginis Semen is comprised in an amount of 1.5-6 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 2-8 parts by weight
  • the Alismatis Rhizoma is comprised in an amount of 2-8 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 2.5-10
  • the Gentianae Scabrae Radix is comprised in an amount of 2-4 parts by weight
  • the Scutellariae Radix is comprised in an amount of 2-4 parts by weight
  • the Gardeniae Fructus is comprised in an amount of 2-4 parts by weight
  • the Anelicae Sinensis Radix is comprised in an amount of 2-4 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 2-4 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 2-4 parts by weight
  • the Bupleuri Radix is comprised in an amount of 2-4 parts by weight
  • the Plantaginis Semen is comprised in an amount of 2-4 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 3-6 parts by weight
  • the Alismatis Rhizoma is comprised in an amount of 3-6 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 4-7 parts
  • Another aspect of the present invention provides a herbal medicinal composition for inhibiting cancer cells including: Forsythiae fructus ( Forsythia suspense (Thunb.) Vahl), Menthae Herba ( Mentha haploclyx BRIQ.), Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium ( Lophatherum gracile Brongniart), Glycyrrhizae Radix, Rhei Rhizoma ( Rheum palmatum Linne), Na 2 SO 4 , and Atractylodis Rhizoma.
  • Forsythiae fructus Forsythia suspense (Thunb.) Vahl
  • Menthae Herba Mentha haploclyx BRIQ.
  • Gardeniae Fructus Scutellariae Radix
  • Lophatheri Folium Lophatherum gracile Brongniart
  • This herbal medicinal composition is extracted, i.e., Forsythiae fructus, Menthae Herba, Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium, Glycyrrhizae Radix, Rhei Rhizoma, Na 2 SO 4 , and Atractylodis Rhizoma are mixed, extracted with water under heating, and then filtrated to remove the dreg thereof.
  • a herbal medicinal extract can be obtained and it can inhibit growth of cancer cells.
  • the Forsythiae fructus is comprised in an amount of 1.5-6 parts by weight
  • the Menthae Herba is comprised in an amount of 1.5-6 parts by weight
  • the Gardeniae Fructus is comprised in an amount of 1.5-6 parts by weight
  • the Scutellariae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Lophatheri Folium is comprised in an amount of 1.5-6 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Rhei Rhizoma is comprised in an amount of 0.5-2 parts by weight
  • the Na 2 SO 4 is comprised in an amount of 0.5-2 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 2-8 parts by weight.
  • the Forsythiae fructus is comprised in an amount of 2-4 parts by weight
  • the Menthae Herba is comprised in an amount of 2-4 parts by weight
  • the Gardeniae Fructus is comprised in an amount of 2-4 parts by weight
  • the Scutellariae Radix is comprised in an amount of 2-4 parts by weight
  • the Lophatheri Folium is comprised in an amount of 2-4 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 2-4 parts by weight
  • the Rhei Rhizoma is comprised in an amount of 0.75-1.5 parts by weight
  • the Na 2 SO 4 is comprised in an amount of 0.75-1.5 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 3-6 parts by weight.
  • Still another aspect of the present invention provides a herbal medicinal composition for inhibiting cancer cells including: Anelicae Sinensis Radix, Ligustici Rhizoma ( Ligusticum chuanxiong Hortorum), Paeoniae (Ovatae) Radix Rubra ( Paeonia veitchii Lynch.), Rehmanniae Radix, Glycyrrhizae Radix, Scutellariae Radix, Chinese Wolfberry Root-bark ( Lycium chinense Mill. Root), Peony Root-bark ( Paeonia suffruticosa Andr. Root), and Atractylodis Rhizoma.
  • This herbal medicinal composition is extracted, i.e., Anelicae Sinensis Radix, Ligustici Rhizoma, Paeoniae (Ovatae) Radix Rubra, Rehmanniae Radix, Glycyrrhizae Radix, Scutellariae Radix, Chinese Wolfberry Root-bark, Peony Root-bark, and Atractylodis Rhizoma are mixed, extracted with water under heating, and then filtrated to remove the dreg thereof.
  • a herbal medicinal extract can be obtained and it can inhibit growth of cancer cells.
  • the Anelicae Sinensis Radix is comprised in an amount of 1.5-6 parts by weight
  • the Ligustici Rhizoma is comprised in an amount of 1.5-6 parts by weight
  • the Paeoniae (Ovatae) Radix Rubra is comprised in an amount of 1.5-6 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Scutellariae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Chinese Wolfberry Root-bark is comprised in an amount of 2.5-10 parts by weight
  • the Peony Root-bark is comprised in an amount of 2.5-10 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 2-8 parts by weight.
  • the Anelicae Sinensis Radix is comprised in an amount of 2-4 parts by weight
  • the Ligustici Rhizoma is comprised in an amount of 2-4 parts by weight
  • the Paeoniae (Ovatae) Radix Rubra is comprised in an amount of 2-4 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 2-4 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 2-4 parts by weight
  • the Scutellariae Radix is comprised in an amount of 2-4 parts by weight
  • the Chinese Wolfberry Root-bark is comprised in an amount of 4-7 parts by weight
  • the Peony Root-bark is comprised in an amount of 4-7 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 2-8 parts by weight.
  • Yet a further aspect of the present invention provides a herbal medicinal composition for inhibiting cancer cells including: Anelicae Sinensis Radix, Ligustici Rhizoma, Peony Root ( Paeonia lactiflora Pall.), Rehmanniae Radix, Atractylodis Rhizoma ( Atractylodes ovata De Canndolle), Glycyrrhizae Radix, Dipsaci Radix ( Dipsacus asper Wall.), Eucommia Bark ( Eucommia ulmoides Oliv), Scutellariae Radix, Dioscoreae Rhizoma ( Dioscorea opposita Thunb.), and Asiatic Wormwood ( Artemisia argyi Levl.
  • This herbal medicinal composition is extracted, i.e., Anelicae Sinensis Radix, Ligustici Rhizoma, Peony Root, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Dipsaci Radix, Eucommia Bark, Scutellariae Radix, Dioscoreae Rhizoma, and Asiatic Wormwood. are mixed, extracted with water under heating, and then filtrated to remove the dreg thereof.
  • a herbal medicinal extract can be obtained and it can inhibit growth of cancer cells.
  • the Anelicae Sinensis Radix is comprised in an amount of 1.5-6 parts by weight
  • the Ligustici Rhizoma is comprised in an amount of 1.5-6 parts by weight
  • the Peony Root is comprised in an amount of 1.5-6 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 1.5-6 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Dipsaci Radix is comprised in an amount of 1.5-6 parts by weight
  • the Eucommia Bark is comprised in an amount of 1.5-6 parts by weight
  • the Scutellariae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Dioscoreae Rhizoma is comprised in an amount of 2.5-10 parts by weight
  • the Asiatic Wormwood is comprised in an amount of 2.5-10 parts by weight.
  • the Anelicae Sinensis Radix is comprised in an amount of 2-4 parts by weight
  • the Ligustici Rhizoma is comprised in an amount of 2-4 parts by weight
  • the Peony Root is comprised in an amount of 2-4 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 2-4 parts by weight
  • the Atractylodis Rhizoma is comprised in an amount of 2-4 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 2-4 parts by weight
  • the Dipsaci Radix is comprised in an amount of 2-4 parts by weight
  • the Eucommia Bark is comprised in an amount of 2-4 parts by weight
  • the Scutellariae Radix is comprised in an amount of 2-4 parts by weight
  • the Dioscoreae Rhizoma is comprised in an amount of 4-7 parts by weight
  • the Asiatic Wormwood. is comprised in an amount of 4-7 parts by weight.
  • Still another aspect of the present invention provides a herbal medicinal composition for inhibiting cancer cells including: Cinnamomum Ramulus ( Cinnamomum cassia Presl.), Paeoniae (Ovatae) Radix Rubra, Glycyrrhizae Radix, Zingiberis Rhizoma ( Zingiber officinale Roscoe), Scutellariae Radix, and Jujubae Fructus ( Ziziphus jujuba Mill.).
  • This herbal medicinal composition is extracted, i.e., Cinnamomum Ramulus, Paeoniae (Ovatae) Radix Rubra, Glycyrrhizae Radix, Zingiberis Rhizoma, Scutellariae Radix, and Jujubae Fructus. are mixed, extracted with water under heating, and then filtrated to remove the dreg thereof.
  • a herbal medicinal extract can be obtained and it can inhibit growth of cancer cells.
  • the Cinnamomum Ramulus is comprised in an amount of 2.5-10 parts by weight
  • the Paeoniae (Ovatae) Radix Rubra is comprised in an amount of 2.5-10 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 2.5-10 parts by weight
  • the Zingiberis Rhizoma is comprised in an amount of 2.5-10 parts by weight
  • the Scutellariae Radix is comprised in an amount of 1.5-6 parts by weight
  • the Jujubae Fructus. is comprised in an amount of 2.5-10 parts by weight.
  • the Cinnamomum Ramulus is comprised in an amount of 4-7 parts by weight
  • the Paeoniae (Ovatae) Radix Rubra is comprised in an amount of 4-7 parts by weight
  • the Glycyrrhizae Radix is comprised in an amount of 4-7 parts by weight
  • the Zingiberis Rhizoma is comprised in an amount of 4-7 parts by weight
  • the Scutellariae Radix is comprised in an amount of 2-4 parts by weight
  • the Jujubae Fructus. is comprised in an amount of 4-7 parts by weight.
  • Still a further aspect of the present invention provides a herbal medicinal composition for inhibiting cancer cells including: Cimicifugae Rhizoma ( Cimicifuga heracleifolia Kam), Rehmanniae Radix, Paeoniae (Ovatae) Radix Rubra, Peony Root-bark, and Scutellariae Radix.
  • This herbal medicinal composition is extracted, i.e., Cimicifugae Rhizoma, Rehmanniae Radix, Paeoniae (Ovatae) Radix Rubra, Peony Root-bark, and Scutellariae Radix are mixed, extracted with water under heating, and then filtrated to remove the dreg thereof.
  • a herbal medicinal extract can be obtained and it can inhibit growth of cancer cells.
  • the Cimicifugae Rhizoma is comprised in an amount of 1-4 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 7.5-30 parts by weight
  • the Paeoniae (Ovatae) Radix Rubra is comprised in an amount of 5-20 parts by weight
  • the Peony Root-bark is comprised in an amount of 5-20 parts by weight
  • the Scutellariae Radix is comprised in an amount of 5-20 parts by weight.
  • the Cimicifugae Rhizoma is comprised in an amount of 1.5-3 parts by weight
  • the Rehmanniae Radix is comprised in an amount of 10-20 parts by weight
  • the Paeoniae (Ovatae) Radix Rubra is comprised in an amount of 8-15 parts by weight
  • the Peony Root-bark is comprised in an amount of 8-15 parts by weight
  • the Scutellariae Radix is comprised in an amount of 8-15 parts by weight.
  • the temperature and time of the heating, the amount of used water, and condensing ratio of the extract are not specifically limited.
  • the heating is to heat the water to 90-100° C. for 60-90 mins, the water is used in an amount of 5-15 times the total weight of the mixture, and the extract is condensed to 1 ⁇ 2-1 ⁇ 4 weight of the water by heating.
  • FIG. 1 is a diagram showing the relation between the survival rate of A549 lung cancer cells and the time of treating A549 lung cancer cells with the extract of Example 5 of the present invention, in which * * * represents p ⁇ 0.001 after Student's t test;
  • FIG. 2 is a diagram showing the rates of A549 lung cancer cells in G0/G1, S, and G2/M phases posterior to being treated with the extract of Example 5 of the present invention, in which *, * *, and * * * represents p ⁇ 0.05, 0.01, and 0.001 after Student's t test, respectively; and
  • FIG. 3 is a diagram showing the rate of A549 lung cancer cells in G0 phase posterior to being treated with the extract of Example 5 of the present invention, in which * * * represents p ⁇ 0.001 after Student's t test.
  • Gentianae Scabrae Radix (11.25 g), Scutellariae Radix (11.25 g), Gardeniae Fructus (11.25 g), Anelicae Sinensis Radix (11.25 g), Rehmanniae Radix (11.25 g), Rehmanniae Radix (11.25 g), Bupleuri Radix (11.25 g), Plantaginis Semen (11.25 g), Atractylodis Rhizoma (15 g), Alismatis Rhizoma (15 g), and Glycyrrhizae Radix (18.75 g) all were cut into slices, respectively.
  • a mixture containing the abovementioned herbal medicinal materials was extracted with water (1200 g) under heating to 90° C. or more for 60-90 minutes, condensed into 400 g, and then filtrated to remove the dreg thereof to afford an extract.
  • a mixture containing the abovementioned herbal medicinal materials was extracted with water (1200 g) under heating to 90° C. or more for 60-90 minutes, condensed into 400 g, and then filtrated to remove the dreg thereof to afford an extract.
  • Anelicae Sinensis Radix (11.25 g), Ligustici Rhizoma (11.25 g), Paeoniae (Ovatae) Radix Rubra (11.25 g), Rehmanniae Radix (11.25 g), Glycyrrhizae Radix (11.25 g), Scutellariae Radix (11.25 g), Chinese Wolfberry Root-bark (18.75 g), Peony Root-bark (18.75 g), and Atractylodis Rhizoma (15 g) all were cut into slices, respectively.
  • a mixture containing the abovementioned herbal medicinal materials was extracted with water (1200 g) under heating to 90° C. or more for 60-90 minutes, condensed into 400 g, and then filtrated to remove the dreg thereof to afford an extract.
  • Anelicae Sinensis Radix (11.25 g), Ligustici Rhizoma (11.25 g), Peony Root (11.25 g), Rehmanniae Radix (11.25 g), Atractylodis Rhizoma (11.25 g), Glycyrrhizae Radix (11.25 g), Dipsaci Radix (11.25 g), Eucommia Bark (11.25 g), Scutellariae Radix (11.25 g), Dioscoreae Rhizoma (18.75 g), and Asiatic Wormwood. (18.75 g) all were cut into slices, respectively.
  • a mixture containing the abovementioned herbal medicinal materials was extracted with water (1200 g) under heating to 90° C. or more for 60-90 minutes, condensed into 400 g, and then filtrated to remove the dreg thereof to afford an extract.
  • a mixture containing the abovementioned herbal medicinal materials was extracted with water (1200 g) under heating to 90° C. or more for 60-90 minutes, condensed into 400 g, and then filtrated to remove the dreg thereof to afford an extract.
  • Cimicifugae Rhizoma (7.5 g), Rehmanniae Radix (56.25 g), Paeoniae (Ovatae) Radix Rubra (37.5 g), Peony Root-bark (37.5 g), and Scutellariae Radix (37.5 g) all were cut into slices, respectively.
  • a mixture containing the abovementioned herbal medicinal materials was extracted with water (1200 g) under heating to 90° C. or more for 60-90 minutes, condensed into 400 g, and then filtrated to remove the dreg thereof to afford an extract.
  • cancer stem cells are those exhibiting characteristics of stem cells in cancer cells. Therefore, if treatment focuses on common cancer cells, cancer stem cells may still survive in a treated tumor. Owing to characteristics of stem cells, the cancer stem cells which survive still can differentiate into commons cancer cells and even form a malignant tumor, resulting in cancer recurrence after treatment. However, if treatment can focus on cancer stem cells, tumors have no survivor of cancer stem cells which can differentiate to supply the number of common cancer cells, and thus can be inhibited.
  • the extracts from the herbal medicinal composition of the present invention were analyzed for the survival rate of A549 lung cancer cells.
  • the cell cycle of cancer cells was checked by flow cytometry to determine whether it was blocked by the extracts of the present invention.
  • the influence of the extracts of the present invention on promotion of cell apoptosis was also confirmed by staining methods. Besides, flow cytometry and two-color fluorescence staining were performed to determine the cytotoxicity of the extracts of the present invention in cancer cells.
  • A549 lung cancer cells were treated with the extracts of Examples 1-6 respectively with a concentration of 10%, 20%, and 100% for 72 hours, and then their survival rates were determined by an MTT assay. The results are shown in the following Table 1.
  • the experimental groups thereof treated with the extract of Example 5 for 24, 48, and 72 hours all have reduced survival rates. Furthermore, as the treating time extends, the survival rates have more significant diversity.
  • A549 lung cancer cells were treated with the half maximal inhibitory dose (35 ⁇ l) of the extract of Example 5 for 24, 48, and 72 hours, and then underwent PI staining followed with flow cytometry to determine DNA level of the lung cancer cells. After analysis of statistics, the result is shown in FIG. 2 .
  • G0/G1, S, G2/M on the horizontal axis represent specific phases in a cell cycle, and the vertical axis represents cell rates of the distinct phases.
  • A549 lung cancer cells were treated with the half maximal inhibitory dose (35 ⁇ A) of the extract of Example 5 for 72 hours, and then underwent PI and Ki67 antibody co-staining followed with flow cytometry to determine the cell rate of the A549 lung cancer cells in the G0 phase. After statistics, the result is shown in FIG. 3 .
  • the herbal medicinal composition and extract thereof provided in the present invention can inhibit growth of cancer cells and make the cancer cells stay in the G0 phase so as to block the continuous division of the cancer cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
US12/923,846 2009-12-10 2010-10-12 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells Abandoned US20110142963A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/613,654 US8449929B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,793 US20130011499A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,774 US20130011503A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,691 US8394430B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,714 US8420134B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/868,253 US8551539B1 (en) 2009-12-10 2013-04-23 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/873,828 US8668940B2 (en) 2009-12-10 2013-04-30 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW098142254 2009-12-10
TW098142254A TWI421088B (zh) 2009-12-10 2009-12-10 中藥組成物水萃取物於製備抑制肺癌細胞生長之藥物上之用途

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US13/613,793 Division US20130011499A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,654 Division US8449929B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,774 Division US20130011503A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,691 Division US8394430B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,714 Division US8420134B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

Publications (1)

Publication Number Publication Date
US20110142963A1 true US20110142963A1 (en) 2011-06-16

Family

ID=44143228

Family Applications (8)

Application Number Title Priority Date Filing Date
US12/923,846 Abandoned US20110142963A1 (en) 2009-12-10 2010-10-12 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,793 Abandoned US20130011499A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,714 Active US8420134B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,654 Active US8449929B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,691 Active US8394430B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,774 Abandoned US20130011503A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/868,253 Active US8551539B1 (en) 2009-12-10 2013-04-23 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/873,828 Active US8668940B2 (en) 2009-12-10 2013-04-30 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

Family Applications After (7)

Application Number Title Priority Date Filing Date
US13/613,793 Abandoned US20130011499A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,714 Active US8420134B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,654 Active US8449929B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,691 Active US8394430B2 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/613,774 Abandoned US20130011503A1 (en) 2009-12-10 2012-09-13 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/868,253 Active US8551539B1 (en) 2009-12-10 2013-04-23 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
US13/873,828 Active US8668940B2 (en) 2009-12-10 2013-04-30 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

Country Status (2)

Country Link
US (8) US20110142963A1 (zh)
TW (1) TWI421088B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670805A (zh) * 2012-05-15 2012-09-19 张化 一种治疗骨病的软膏剂
CN103585347A (zh) * 2013-10-30 2014-02-19 杨光英 一种治疗烧烫伤的中药组合物及其制备方法
CN108042600A (zh) * 2017-12-27 2018-05-18 中南大学 杜仲木脂素及杜仲提取物在制备Hsp90α抑制剂和抗肿瘤药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103055100B (zh) * 2010-07-21 2014-12-03 李政育 抑制癌细胞生长的中药组合物及其中药萃取物
KR101350144B1 (ko) * 2013-05-03 2014-01-10 재단법인 통합의료진흥원 팔물탕 추출물을 포함하는 골수유래 줄기세포 증식 촉진용 조성물
CN103301170A (zh) * 2013-05-20 2013-09-18 吴全顶 子午虫药物
CN103494905B (zh) * 2013-09-28 2015-11-18 中国农业科学院兰州畜牧与兽药研究所 一种防治仔猪腹泻的药物组合物及其制备方法和应用
AU2015314911B2 (en) * 2014-09-12 2020-01-02 Kenneth E. Cisek Films and bags with visually distinct regions and methods of making the same
FR3032353B1 (fr) * 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
KR101941399B1 (ko) * 2015-06-03 2019-04-17 오피 나노 컴퍼니, 리미티드 비-소세포 폐암의 치료를 위한 치료방법 및 이를 위한 조성물
CN105125878A (zh) * 2015-10-17 2015-12-09 张景悦 一种预防新生儿脐炎的中药药物及其制备方法
CN105267793B (zh) * 2015-11-26 2017-11-24 启迪古汉集团衡阳中药有限公司 一种中药组合物的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200719837A (en) * 2005-11-21 2007-06-01 Uni President Entpr Corp Process methods and compositions to treat dysmenorrhea and premenstrual syndrome
WO2008119130A1 (en) * 2007-04-02 2008-10-09 Medcina Group Pty Ltd Herbal compositions and methods for treating premenstrual syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200719837A (en) * 2005-11-21 2007-06-01 Uni President Entpr Corp Process methods and compositions to treat dysmenorrhea and premenstrual syndrome
WO2008119130A1 (en) * 2007-04-02 2008-10-09 Medcina Group Pty Ltd Herbal compositions and methods for treating premenstrual syndrome

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670805A (zh) * 2012-05-15 2012-09-19 张化 一种治疗骨病的软膏剂
CN103585347A (zh) * 2013-10-30 2014-02-19 杨光英 一种治疗烧烫伤的中药组合物及其制备方法
CN108042600A (zh) * 2017-12-27 2018-05-18 中南大学 杜仲木脂素及杜仲提取物在制备Hsp90α抑制剂和抗肿瘤药物中的应用

Also Published As

Publication number Publication date
US8394430B2 (en) 2013-03-12
US8449929B2 (en) 2013-05-28
US8551539B1 (en) 2013-10-08
US20130243892A1 (en) 2013-09-19
US20130017275A1 (en) 2013-01-17
TW201119666A (en) 2011-06-16
US20130011499A1 (en) 2013-01-10
TWI421088B (zh) 2014-01-01
US20130011503A1 (en) 2013-01-10
US8420134B2 (en) 2013-04-16
US20130236576A1 (en) 2013-09-12
US20130004605A1 (en) 2013-01-03
US20130004597A1 (en) 2013-01-03
US8668940B2 (en) 2014-03-11

Similar Documents

Publication Publication Date Title
US8668940B2 (en) Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells
EP2474314B1 (en) Antiphlogistic, antioncotic and analgesic chinese herbal composition preparative method and usage thereof
CN103768537A (zh) 用于治疗气滞血瘀型心绞痛的中药组合物
CN103784888A (zh) 治疗气虚血瘀型冠状动脉粥样硬化性心脏病的中药
CN102423438A (zh) 一种用于抗癌的双组方药物及其制备方法
CN103055100B (zh) 抑制癌细胞生长的中药组合物及其中药萃取物
CN113769047A (zh) 湿疹、过敏/变态反应综合抗微生物疗法
CN103055027B (zh) 抑制癌细胞生长的中药组合物及其中药萃取物
TWI498119B (zh) 中藥組成物水萃取物於製備抑制肺癌細胞生長之藥物上之用途
TWI511735B (zh) 中藥組成物水萃取物於製備抑制肺癌細胞生長之藥物上之用途
TWI532492B (zh) 中藥組成物水萃取物於製備抑制肺癌細胞生長之藥物上之用途
TWI491403B (zh) 中藥組成物水萃取物於製備抑制肺癌細胞生長之藥物上之用途
CN103070982B (zh) 抑制癌细胞生长的中药组合物及其中药萃取物
TWI491399B (zh) 中藥組成物水萃取物於製備抑制肺癌細胞生長之藥物上之用途
CN100382819C (zh) 一种治疗肾炎的胶囊
CN103071069A (zh) 抑制癌细胞生长的中药组合物及其中药萃取物
CN108379543A (zh) 一种治疗月子病的中药配方
CN102335301A (zh) 抑制癌细胞生长的中药组成物及其中药萃取物
CN1223119A (zh) 内异症中药制剂
CN106310095A (zh) 一种用于治疗妇科病的内服药
CN103071133A (zh) 抑制癌细胞生长的中药组合物及其中药萃取物
CN114652772A (zh) 一种治疗前列腺炎的中药组合物及其制备方法和应用
CN114028525A (zh) 一种治疗胃癌的中药组合物
CN101816748B (zh) 一种防治犬腹泻症的中药及其制备方法
CN113116987A (zh) 一种用于治疗肿瘤的中药组合物及其制备方法

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION